GVB Biopharma, a global producer of cannabinoids, has opened an isolation facility. 

The facility, developed over nearly two years of planning and engineering, allows GVB Biopharma to meet the evolving demands of the global hemp and cannabinoid markets.

"Our new isolation facility represents a major milestone for GVB Biopharma," said Drew Spiegel, CEO of GVB Biopharma. "We have designed this operation to ensure ultra-high throughput capacity while maintaining strict nutraceutical cGMP compliance. As a result, we're positioned to significantly increase production output and meet the rigorous standards required by our ever-expanding, sophisticated customer base."

The facility has the capacity to produce more than 300,000 kg of isolates per year. This capacity positions GVB Biopharma to achieve up to $100 million in annual recurring revenue (ARR) while maintaining product integrity and consistency. With larger batch sizes and proprietary separation and refinement processes, the facility delivers higher-efficiency yields.

"From day one, our focus has been on setting a new industry standard in both scale and precision," said Phil Swindells, COO of GVB Biopharma. "This cutting-edge facility underscores our commitment to delivering top-quality, high-volume cannabinoid isolates. We're excited to meet the evolving needs of our clients with this unprecedented level of production and consistency."